A leukaemia combination therapy could help revive the fortunes of Roche and AbbVie, following late-stage trial results showing it significantly reduces risk of progression in CLL compared w
Immunocore has gained a Promising Innovative Medicines (PIM) designation in the UK for its candidate immunotherapy for patients with metastatic uveal melanoma, a rare tumour of the eye.
